UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~April 61, 2024

Innoveren Scientific, Inc.

(Exact Name of Registrant as Specified in Charter)

Nevada

001-36763

46-3312262

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

151 W4th St., Ste 223,

Cincinnati, OH

45202

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code:

(844) 633-6839

201 E Kennedy Blvd, Suite 700 Tampa, FL, 33602

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Common Stock

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 75.0102, ~~Regulation~~Departure FDof ~~Disclosure~~Directors or Principal Officers; Election of Directors; Appointment of Principal Officers;

On March 626, 2024, Innoveren Scientific, Inc. (the “Company”) issued to certain executive officers an aggregate of 186,048 shares of common stock in lieu of accrued salary at a ~~press~~rate ~~release~~of $0.25 Aper ~~copy~~share for amounts owed and an aggregate of 213,952 shares for payment of directors’ fees owed. In addition, the ~~press~~Company ~~release~~issued isits ~~furnished~~officers and directors an aggregate of 400,000 options to ~~hereto~~purchase ascommon ~~Exhibit~~stock 99at $0.103 ~~and~~per ~~incorporated~~share ~~herein~~which bywas ~~reference~~above the closing price of the Company’s common stock on March 25, 2024.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

The following exhibits are filed as part of this report:

Item 9.01 Exhibits

Exhibit No.		Description
99.1		Press Release dated March 6, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Innoveren Scientific, Inc.
Date: March 6, 2024	By:	/s/ Jeremy Daniel
Date: April 1, 2024	By:	/s/ Jeremy Daniel
		Jeremy Daniel
		Chief Financial Officer

Filing Compare · Innoveren Scientific, Inc.